Relationship of Total Antioxidant Capacity and Endothelin-1 levels in prehypertensive individuals among population attaining a sedentary lifestyle in central India

Abstract

Objective: As known, hypertension has relation with increased peripheral vascular resistance. Vascular tone is regulated by multiple mediators; among them is Endothelin-1. Endothelin-1 (ET-1) is one of the most potent vasoconstrictors known to date. While its plasma /serum concentrations are elevated in some forms of hypertension. Prehypertension is one step towards hypertension, hence the same factor is involved in it. Oxidative stress is also found to be involved in pathogenesis of hypertension .Therefore our present study is designed to find the relationship between ET-1 levels and Total antioxidant capacity (TAC) in Prehypertension. Methods: Total 100 prehypertensive cases and 100 sex matched controls were enrolled in this study. Inclusion criteria include patients with systolic blood pressure (SBP) in the range of 120 to 139 mmHg and diastolic blood pressure (DBP) in the range 80-90 mmHg, while patients with BP ≥140/90 mmHg, diabetes mellitus (DM), Stroke, coronary artery disease (CAD) and myocardial infarction (MI) were excluded. Plasma ET -1 and plasma total antioxidant capacity were measured .We estimated ET -1 levels and TAC levels in Prehypertensive cases and Normotensive controls. Students T test were used for statistical analyses. Results: Plasma ET-1 levels were found significantly (p:0.001) higher in prehypertensive cases as compared to normotensive controls. In contrary to this, Plasma Total Antioxidant capacity was found extremely significantly lower in prehypertensive cases as compared to normotensive controls(p<0.0001). Conclusion: The study demonstrated that in Prehypertensives, there is an inverse relationship between Endothelin-1 and Total antioxidant capacity.

Keywords

• Endothelin-1,Total Antioxidant Capacity,DBP,SBP

References

1. 1. Coffman TM. Under pressure: the search for the essential mechanisms of hypertension. Nat Med 2011;17:1402-9.
2. 2. Lenfant C, Chobanian AV, Jones DW, Roccella EJ. Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension 2003;41:1178–9.
3. 3. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure- related disease, 2001. Lancet 2008;371:1513-8.
4. 4. Coffman TM. Under pressure: the search for the essential mechanisms of hypertension. Nat Med 2011;17:1402-9.
5. 5. Yanagisawa M et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–415.
6. 6. Masaki T, Kimura S, Yanagisawa N, Goto K. Molecular and cellular mechanism of endothelin regulation: implications for vascular function. Circulation 1991; 84: 1457–1468.
7. 7. Saito Y, Nakao K, Mukoyama M, Imura M. Increased plasma endothelin level in patients with essential hypertension. N Engl J Med 1990; 322: 205.
8. 8. Kohno M et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 1990; 88: 614–618.

9. 9. Schiffrin EL, Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens 1991; 4: 303–308.
10. 10. Davenport AP et al. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci 1990; 78: 261–264.
11. 11. Bartosz G. Total antioxidant capacity. Adv Clin Chem 2003;37:219– 92.
12. 12. Serafini M, Del Rio D. Understanding the association between dietary antioxidants, redox status and disease: is the total antioxidant capacity the right tool? Redox Rep 2004;9:145–52.
13. 13. D Koracevic ,G Koracevic ,V Djordjevic,S Andrejevic ,V Cosic.Measurement of antioxidant activity in human fluids.F Clin Pathol 2001;54:356-361.
14. 14. Ando K et al. Presence of immunoreactive Endothelin in human plasma. Febs Lett 1989; 245: 164–166.
15. 15. Furchgott RF ,Zawadzki jv (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.Nature 288:373-376.
16. 16. Furchgott RF ,Vanhoutte PM (1989) Endothelium –derived relaxing and contracting factors,FASEB J 3:2007-2008.
17. 17. Giaid A ,Yanagisawa M,Langleban D,Michel RP,Levy R,Shennib H,Kimura S,Masaki T,Duguid WP,Stewart DJ (1993).Expression of Endothelin 1 in the lungs of patients with pulmonary hypertension.N Engl J Med 328:1732-1739.
18. 18. Gillespie MN, Owasoyo JO, McMurtry IF, O'Brien RF (1986) Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in cul-ture. J Pharmacol Exp Ther 236:339-343
19. 19. Goetz KL, Wang BC, Madwed JB, Zhu JL, Leadley RJ Jr (1988) Cardiovascular, renal, and endocrine responses to in-travenous endothelin in conscious dogs. Am J Physiol 255: R1064-R1068
20. 20. Goligorsky MS, Iijima K, Morgan M, Yangisawa M, Masaki T, Lin L, Nasjletti A, Kaskel F, Frazer M, Badr K F (1991)
21. 21. Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension 2008;52:452-9.
22. 22. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000;102:2434-40.
23. 23. Krouf, D., M. Bouchenak, B. Mohammed, A. Cherrad, J.L. Belleville and J.L. Prost, 2003. Changes in serum lipids and antioxidant status in west Algerian patients with essential hypertension treated with acetutolol compared to healthy subjects. Med. Sci. Monit., 9(8): 1109-1115.
24. 24. Onuoha S.C.,. Uzuegbu U.E and Apu Murphy,2012. Total Antioxidant Capacity (Tac) in Hypertensive Patients. Asian Journal of Medical Sciences 5(2): 37-40, 2040-8765.
25. 25. Letizia C, Iannaccone A, Cerci S, et al. Circulating endothelin-1 in non-insulin-dependent diabetic patients with retinopathy. Horm Metab Res 1997;29:247–51.